Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) develops and commercializes clinician-administered therapies for dermatologic diseases, including skin cancers. Its commercial product, YCANTH, is a cantharidin drug-device combination approved in the United States for molluscum in adults and children aged two and older; the… From the company’s description.
Over the twelve months to Jun 30, 2026, Verrica Pharmaceuticals Inc. reported revenue of $30.32M, up 106.2% from a year earlier, and a net loss of $31.18M. Its operating margin was −93.6%, and operations used $13.35M in cash. In fiscal 2025, it reported revenue of $35.58M, up 370.2% from fiscal 2024, and a net loss of $17.89M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Verrica Pharmaceuticals Inc. does
In the company’s own words
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) develops and commercializes clinician-administered therapies for dermatologic diseases, including skin cancers. Its commercial product, YCANTH, is a cantharidin drug-device combination approved in the United States for molluscum in adults and children aged two and older; the company sells it to healthcare providers, including dermatologists, pediatricians and select primary care practices. Verrica is developing YCANTH for common warts and VP-315, an injectable oncolytic peptide therapy, for basal cell carcinoma and other potential dermatologic oncology uses. The company’s U.S. commercialization is supported by a specialized sales organization, while Torii Pharmaceutical holds Japanese rights to cantharidin products for molluscum and common warts and launched YCANTH in Japan in 2026. Verrica also licenses VP-315 technology from Lytix BioPharma. It had approximately 40 U.S. field sales representatives as of December 31, 2025, and reported $2.3 million in license and collaboration revenue related to supplies and development activity with Torii for 2025. Its website is https://verrica.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WEST CHESTER, PA
- Fiscal year end
- December
- CIK
- 1660334
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Verrica Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Verrica Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Verrica Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Verrica Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Verrica Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”